EVOLENT HEALTH INC - A (EVH)
US30050B1017 - Common Stock
Overall EVH gets a fundamental rating of 4 out of 10. We evaluated EVH against 37 industry peers in the Health Care Technology industry. EVH may be in some trouble as it scores bad on both profitability and health. EVH is growing strongly while it also seems undervalued. This is an interesting combination
1. Profitability
1.1 Basic Checks
EVH had positive earnings in the past year.
EVH had a positive operating cash flow in the past year.
In the past 5 years EVH always reported negative net income.
The reported operating cash flow has been mixed in the past 5 years: EVH reported negative operating cash flow in multiple years.
1.2 Ratios
EVH has a better Return On Assets (-4.17%) than 75.00% of its industry peers.
Looking at the Return On Equity, with a value of -8.50%, EVH is in the better half of the industry, outperforming 75.00% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -8.5% | ||
| ROIC | N/A |
ROA(3y)-3%
ROA(5y)-10.71%
ROE(3y)-6.36%
ROE(5y)-21.15%
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
Looking at the Gross Margin, with a value of 15.96%, EVH is doing worse than 88.89% of the companies in the same industry.
In the last couple of years the Gross Margin of EVH has declined.
The Profit Margin and Operating Margin are not available for EVH so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.96% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-1.68%
GM growth 5Y-13.25%
2. Health
2.1 Basic Checks
EVH does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, EVH has more shares outstanding
The number of shares outstanding for EVH has been increased compared to 5 years ago.
The debt/assets ratio for EVH has been reduced compared to a year ago.
2.2 Solvency
EVH has an Altman-Z score of 1.16. This is a bad value and indicates that EVH is not financially healthy and even has some risk of bankruptcy.
EVH has a Altman-Z score (1.16) which is comparable to the rest of the industry.
EVH has a debt to FCF ratio of 5.47. This is a neutral value as EVH would need 5.47 years to pay back of all of its debts.
With a decent Debt to FCF ratio value of 5.47, EVH is doing good in the industry, outperforming 69.44% of the companies in the same industry.
A Debt/Equity ratio of 0.49 indicates that EVH is not too dependend on debt financing.
With a Debt to Equity ratio value of 0.49, EVH is not doing good in the industry: 69.44% of the companies in the same industry are doing better.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | 5.47 | ||
| Altman-Z | 1.16 |
ROIC/WACCN/A
WACC9.69%
2.3 Liquidity
A Current Ratio of 1.04 indicates that EVH should not have too much problems paying its short term obligations.
EVH's Current ratio of 1.04 is on the low side compared to the rest of the industry. EVH is outperformed by 63.89% of its industry peers.
EVH has a Quick Ratio of 1.04. This is a normal value and indicates that EVH is financially healthy and should not expect problems in meeting its short term obligations.
EVH has a Quick ratio of 1.04. This is in the lower half of the industry: EVH underperforms 63.89% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 21.33% over the past year.
EVH shows a strong growth in Revenue. In the last year, the Revenue has grown by 37.65%.
Measured over the past years, EVH shows a very strong growth in Revenue. The Revenue has been growing by 25.65% on average per year.
EPS 1Y (TTM)21.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-86.67%
Revenue 1Y (TTM)37.65%
Revenue growth 3Y28.54%
Revenue growth 5Y25.65%
Sales Q2Q%21.6%
3.2 Future
The Earnings Per Share is expected to grow by 31.61% on average over the next years. This is a very strong growth
Based on estimates for the next years, EVH will show a quite strong growth in Revenue. The Revenue will grow by 17.75% on average per year.
EPS Next Y54.6%
EPS Next 2Y37.5%
EPS Next 3Y34.76%
EPS Next 5Y31.61%
Revenue Next Year31.98%
Revenue Next 2Y22.89%
Revenue Next 3Y20.43%
Revenue Next 5Y17.75%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 12.80, which indicates a correct valuation of EVH.
Compared to the rest of the industry, the Price/Earnings ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 97.22% of the companies listed in the same industry.
EVH is valuated cheaply when we compare the Price/Earnings ratio to 28.65, which is the current average of the S&P500 Index.
A Price/Forward Earnings ratio of 7.00 indicates a rather cheap valuation of EVH.
Based on the Price/Forward Earnings ratio, EVH is valued cheaper than 100.00% of the companies in the same industry.
When comparing the Price/Forward Earnings ratio of EVH to the average of the S&P500 Index (23.56), we can say EVH is valued rather cheaply.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.8 | ||
| Fwd PE | 7 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of EVH indicates a somewhat cheap valuation: EVH is cheaper than 77.78% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of EVH indicates a rather cheap valuation: EVH is cheaper than 88.89% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 12.23 | ||
| EV/EBITDA | 17.38 |
4.3 Compensation for Growth
EVH's low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
A more expensive valuation may be justified as EVH's earnings are expected to grow with 34.76% in the coming years.
PEG (NY)0.23
PEG (5Y)N/A
EPS Next 2Y37.5%
EPS Next 3Y34.76%
5. Dividend
5.1 Amount
No dividends for EVH!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
EVOLENT HEALTH INC - A
NYSE:EVH (11/21/2024, 3:52:00 PM)
11.65
+0.34 (+3.01%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Technology
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap1.34B
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 12.8 | ||
| Fwd PE | 7 | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)0.23
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -4.17% | ||
| ROE | -8.5% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 15.96% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.99
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.49 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 1.04 | ||
| Quick Ratio | 1.04 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
High Growth Momentum
Growth
EPS 1Y (TTM)21.33%
EPS 3YN/A
EPS 5Y
EPS Q2Q%
EPS Next Y54.6%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)37.65%
Revenue growth 3Y28.54%
Revenue growth 5Y
Sales Q2Q%
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y